 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Daewoong Pharmaceutical Co. said on the 19th that its clinical study of "Bersiporocin," which is being developed as a new idiopathic pulmonary fibrosis drug, has been selected as one of the top 10 best projects for the 2023 National Drug Development Project of the National Drug Development Project (KDDF).
Idiopathic pulmonary fibrosis is an incurable disease in which collagen accumulates in the lungs and loses lung function, which occurs at the frequency of about 13 people per 100,000 people worldwide. Although the prognosis is not good, with a five-year survival rate of only 40% after diagnosis, previously licensed treatments are in high demand for the development of new treatments due to severe side effects.
The Bersiporocin (DWN 12088) study, which Daewoong Pharmaceutical is developing as the world's first new drug, was selected as an excellent task in the "High performance" category. High performance is awarded to tasks that have achieved technological transfer results or achieved target milestone early.
The awards ceremony was held at the Dragon City Hotel in Yongsan-gu, Seoul on the 12th. In the presentation, Lee Ji-sun, head of Daewoong Pharmaceutical's clinical development center, presented the background, competitiveness and performance of Bersiporocin as a presenter. Director Lee said, "We plan to complete a phase 2 clinical study in 2025 to evaluate the safety and efficacy of a total of 102 patients with idiopathic pulmonary fibrosis. Daewoong Pharm aims to improve the competitiveness of Vercyposin by expanding indications other than pulmonary fibrosis and global technology transfer."
Bersiporocin is the world's first PRS (Prolyl-tRNA Synthetase) inhibitory antifibrotic drug that Daewoong Pharmaceutical is developing with its own technology. It is a mechanism that inhibits the excessive production of collagen, which causes fibrosis, by reducing the PRS protein action that affects collagen production.
Bersiporocin identified safety and pharmacologic characteristics in a total of 162 healthy subjects in clinical trials conducted in Korea and Australia. Currently, Phase II clinical trials are underway in Korea and the United States.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
